	1	Ast et al., "Antisense oligonucleotide binding to U5 snRNP induces a conformational change that exposes the conserved loop of U5 snRNA, Nucleic Acids Research, 25(17):3508-3513 (1997)	☐
	2	Jin et al., "Polypyrimidine Tract-Binding Protein Down-Regulates Fibroblast Growth Factor Receptor 1 alpha-Exon Inclusion," Cancer Research, 63:6154-6157 (2003)	☐
	3	Mallardo et al., "Microtubule-dependent Organization of Vaccinia Virus Core—derived Early mRNAs into Distinct Cytoplasmic Structures," Molecular Biology of the Cell, 12:3875-3891 (2001)	☐
	4	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," The Journal of Biological Chemistry, 278(9):7108-7118 (2003)	☐
	5	FISH & RICHARDSON P.C., Amendment in Reply to Action dated June 3, 2009 in U.S. App. Ser. No. 10/594,706, filed December 2, 2009, 16 pages	☐
	6	U.S. EXAMINER DANA H. SHIN, USPTO Final Office Action in U.S. App. Ser. No. 10/594,706, mailed March 10, 2010, 13 pages	☐

If you wish to add additional non-patent literature document citation information please click the Add button [Add]

EXAMINER SIGNATURE

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	10/15/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.